Genetic polymorphisms in the apoptosis-associated genes FAS and FASL and breast cancer risk

Carcinogenesis

Volumn 28, Issue 12, 2007, Pages 2548-2551

  Crew, Katherine D ^a   Gammon, Marilie D ^a   Terry, Mary Beth ^b   Zhang, Fang Fang ^c   Agrawal, Meenakshi ^d   Eng, Sybil M ^e   Sagiv, Sharon K ^a   Teitelbaum, Susan L ^f   Neugut, Alfred I ^b   Santella, Regina M ^d  

^a IL   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

^c UNIVERSITY OF NORTH TEXAS HEALTH SCIENCE CENTER   (United States)

^d Pfizer ^*  (United States)

^e PFIZER INC   (United States)

^f MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; CYTOSINE; FAS ANTIGEN; FAS LIGAND; GUANINE; POLYCYCLIC AROMATIC HYDROCARBON; THYMINE;

5' UNTRANSLATED REGION; ADULT; AGED; ALLELE; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DNA ADDUCT; DOWN REGULATION; ENVIRONMENTAL EXPOSURE; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; LACTATION; MAJOR CLINICAL STUDY; POPULATION RESEARCH; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; UNITED STATES; WILD TYPE;

5' UNTRANSLATED REGIONS; ADULT; AGED; ALCOHOL DRINKING; ANTIGENS, CD95; APOPTOSIS; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CONTRACEPTIVES, ORAL, HORMONAL; DNA ADDUCTS; ENVIRONMENTAL EXPOSURE; ESTROGEN REPLACEMENT THERAPY; FAS LIGAND PROTEIN; FEMALE; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LACTATION; NEW YORK; POLYCYCLIC HYDROCARBONS, AROMATIC; POLYMORPHISM, GENETIC; RISK; TOBACCO USE DISORDER;

EID: 36949024773     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgm211     Document Type: Article

References (42)

1. KrammerP.H. et al. (1994) Regulation of apoptosis in the immune system. Curr. Opin. Immunol., 6, 279-289.
2. Griffith,T.S. et al. (1995) Fas ligand-induced apoptosis as a mechanism of immune privilege. Science, 270, 1189-1192.
3. Strand,S. et al. (1996) Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells-a mechanism of immune evasion? Nat. Med., 2, 1361-1366.
4. Rieux-Laucat,F. et al. (1995) Mutations in Fas associated with human lymphoproliferative syndrome and autoimmunity. Science, 268, 1347-1349.
5. Lee,S.H. et al. (1999) Alterations of Fas(APO-1/CD95) gene in transitional cell carcinomas of urinary bladder. Cancer Res., 59, 3068-3072.
6. Lee,S.H. et al. (1999) Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer, Oncogene, 18, 3754-3760.
7. Butler,L.M. et al. (1998) Down-regulation of Fas gene expression in colon cancer is not a result of allelic loss or gene rearrangement. Br J. Cancer, 77, 1454-1459.
8. Shimonishi,T. et al. (2000) Up-regulation of Fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance. Hepatology, 32, 761-769.
9. Huang,Q.R. et al. (1997) Identification and characterization of polymorphisms in the promoter region of the hum4n Apo-1/Fas (CD95) gene. Mol. Immunol., 34, 577-582.
10. Sibley,K. et al. (2003) Functional FAS promoter polymorphisms am associated with increased risk of acute myeloid leukemia. Cancer Res. 63, 4327-4330.
11. Kanemitsu,S. et al. (2002) A functional polymorphism in fas (CD95/ APO-1) gene promoter associated with systemic lupus erythematosus. J. Rheumatol., 29, 1183-1188.
12. Wu,J. et al. (2003) A novel polymorphic CAAT/enhancer-binding protein beta element in the FasL gene promoter alters Fas ligand expression: A candidate background gene in African American systemic lupus erythematosus patients. J. Immunol., 170, 132-138.
13. Wang,L.E. et al. (2003) Fas A670G polymorphism, apoptotic capacity in lymphocyte cultures, and risk of lung cancer. Lung Cancer, 42, 1-8.
14. Sun,T. et al. (2004) Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst., 96, 1030-1036.
15. Yang,S. et al. (2005) [Genetic polymorphisms of apoptosis-associated genes FAS and FASL and risk of colorectal cancer]. Zhonghua Yi Xue Za Zhi, 85, 2132-2135.
16. Lai,H.C. et al. (2005) Genetic polymorphisms of FAS and FASL (CD95/CD95L) genes in cervical carcinogenesis: An analysis of haplotype and gene-gene interaction. Gynecol. Oncol., 99, 113-118.
17. Lai,H.C. et al. (2003) Single nucleotide polymorphism at Fas promoter is associated with cervical carcinogenesis. Int. J. Cancer 103, 221-225.
18. Sun,T. et al. (2005) FASL - 844C polymorphism is associated with increased activation-induced T cell death and risk of cervical cancer. J. Exp. Med., 202, 967-974.
19. Zhang,B. et al. (2007) Functional polymorphisms in FAS and FASL contribute to increased apoptosis of tumor infiltration lymphocytes and risk of breast cancer. Carcinogenesis, 28, 1067-1073.
20. Krippl,P. et al. (2004) Re: Polymorphisms of death pathway genes FAS and FASL in esophageal squamous-cell carcinoma. J. Natl Cancer Inst., 96, 1478-1479; author reply 1479.
21. Suzuki,N. et al. (1999) Effects of cigarette smoking on Fas/Fas ligand expression of human lymphocytes. Cell. Immunol., 192, 48-53.
22. Bijl,M. et al. (2001) Effects of smoking on activation markers, Fas expression and apoptosis of peripheral blood lymphocytes. Eur J. Clin. Invest., 31, 550-553.
23. Minana,J.B. et al. (2002) Mitochondrial oxidative stress and CD95 ligand: A dual mechanism for hepatocyte apoptosis in chronic alcoholism. Hepatology, 35, 1205-1214.
24. Zhou,Z. et al. (2001) Ethanol-induced apoptosis in mouse liver: Fas- and cytochrome c-mediated caspase-3 activation pathway. Am. J. Pathol., 159, 329-338.
25. Dong,L. et al. (1999) Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J. Biol. Chem., 274, 32099-32107.
26. Gammon,M.D. et al. (2002) The Long Island Breast Cancer Study Project: Description of a multi-institutional collaboration to identify environmental risk factors for breast cancer. Breast Cancer Res. Treat., 74, 235-254.
27. Gammon,M.D. et al. (2002) Environmental toxins and breast cancer on Long Island. I. Polycyclic aromatic hydrocarbon DNA adducts [see comment]. Cancer Epidemiol. Biomarkers Prev., 11, 677-685.
28. Santella,R.M. et al. (1992) Cigarette smoking related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells. Carcinogenesis, 13, 2041-2045.
29. Hosmer,D. et al. (1989) Applied Logistic Regression. John Wiley & Sons, New York.
30. Muschen,M. et al. (2000) Defining CD95 as a tumor suppressor gene. J. Mol. Med., 78, 312-325.
31. Peters,A.M. et al. (1999) Defective apoptosis due to apoint mutation in the death domain of CD95 associated with autoimmune lymphoproliferative syndrome, T-cell lymphorna, and Hodgkin's disease. Exp. Hematol., 27, 868-874.
32. Kennedy,B.J. (1962) Massive estrogen administration in premenopausal women with metastatic breast cancer. Cancer, 15, 641-648.
33. Carter,A.C. et al. (1977) Diethylstilbestrol: Recommended dosages for different categories of breast cancer patients. Report of the Cooperative Breast Cancer Group. JAMA, 237, 2079-2088.
34. Song,R.X. et al. (2001) Effect of long-term estrogen deprivation on apoptotic responses of breast cancer cells to 17beta-estradiol. J. Natl Cancer Inst., 93, 1714-1723.
35. Mor,G. et al. (2000) Regulation of Fas ligand expression in breast cancer cells by estrogen: Functional differences between estradiol and tamoxifen. J. Steroid Biochem Mol. Biol., 73, 185-194.
36. Menzie,C.A. et al. (1992) Exposure to carcinogenic PAHs in the environment. Environ. Sci. Technol., 26, 1278-1284.
37. el-Bayoumy,K. (1992) Environmental carcinogens that may be involved in human breast cancer etiology. Chem Res. Toxicol., 5, 585-590.
38. Li,D et al. (1996) Aromatic DNA adducts in adjacent tissues of breast cancer patients: Clues to breast cancer etiology. Cancer Res. 56, 287-293.
39. Tang,D. et al. (2002) Polymorphisms in the DNA repair enzyme XPD are associated with increased levels of PAH-DNA adducts in a case-control study of breast cancer. Breast Cancer Res. Treat., 75, 159-166.
40. Gammon,M.D. et al. (2004) Polycyclic aromatic hydrocarbon-DNA adducts and breast cancer: A pooled analysis. Arch. Environ. Health 59, 640-649.
41. Shantakumar,S. et al. (2005) Residential environmental exposures and other characteristics associated with detectable PAH-DNA adducts in peripheral mononuclear cells in a population-based sample of adult females. J. Expo. Anal. Environ. Epidemiol., 15, 482-490.
42. Vaca,C.E. et al. (1995) 32P-postlabelling determination of DNA adducts of malonaldehyde in humans: Total white blood cells and breast tissue. Carcinogenesis, 16, 1847-1851.